Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 654 results for "Tecfidera"

Biogen to fork over $1.25B-plus to settle blockbuster Tecfidera patent fight with Forward
FiercePharma

Biogen to pay $1.25 bn to settle license agreement with Forwar...

Biogen has agreed to enter into a settlement and license agreement with Forward Pharma, subject to the approval of Forward Pharma's shareholders and other customary conditions. The license agreement will provide Biogen an irrevocable license to all ... PharmaBiz, 1 day ago
[x]  

19 images for Tecfidera

pharmaphorum, 2 days ago
Medical Marketing And Media, 2 days ago
Yahoo! Finance, 2 days ago
Scrip Intelligence, 1 day ago
FiercePharma, 1 day ago
Zacks.com, 1 day ago
Bloomberg, 1 month ago
Investor's Business Daily, 1 month ago
FiercePharma, 2 months ago
Pharma Letter, 2 months ago

Biogen's $1.25 billion agreement with Forward Pharma is a very expensive insurance policy on its most valuable drug

Multiple sclerosis drug Tecfidera is Biogen's largest
 Yahoo! Finance2 days ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 9, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 week ago

Tecfidera may limit visual problems for MS patients (19/01/17)

Scientists who genetically silenced the transcription factor Nrf2 in a study of mice found it caused visual impairment and retinal ganglion cell (RGC) degeneration in MS. The study, published in scientific journal Molecular Vision, was undertaken ...
 MS-UK.org23 hours ago

Biogen settles in Tecfidera patent case

Brief Author By @BioWriterChik • Published Jan. 17, 2017 Dive Brief: As predicted by some analysts, Forward Pharma settled with Biogen on their patent dispute regarding the active ingredient for the blockbuster multiple ...
 BioPharma Dive2 days ago Biogen cuts jobs in MA manufacturing slimdown  BioPharma Dive1 month ago
Bloomberg

Biogen moves Michel Vounatsos up to succeed Scangos as CEO

Having helped Biogen work its way through a slowdown in sales of MS powerhouse Tecfidera, Biogen exec Michel Vounatsos will now help the company find its path to the future as its new CEO. The Cambridge, Massachusetts, biotech announced today ...
 FiercePharma1 month ago Biogen's a Tough Gig for Any CEO  Bloomberg1 month ago Biogen names new CEO  pharmaphorum1 month ago Biogen Promotes Vounatsos to CEO, Capping Scangos 6-Year Run  Xconomy1 month ago

PTAB Holds Oral Hearings In Tecfidera Patent IPR and Interference

, the USPTO Patent Trial and Appeal Board (PTAB) held oral hearings in two different inter partes proceedings involving the Biogen Tecfidera® patent with the latest expiation date. First, it heard arguments in the Inter Partes Review (IPR) brought ...
 National Law Review1 month ago Biogen's Tecfidera faces outside pressure  BioPharma Dive1 month ago

Biogen's Tecfidera was the Most Successful Drug Approved in 2013, But Other Mass. Biotechs Didn't do So Well

A new report argues that Biogen's blockbuster multiple sclerosis treatment Tecfidera was the biggest commercial success of roughly two dozen novel drugs approved in 2013, but other biotech firms in the Bay State didn't fare quite as well. In a ...
 BioSpace2 months ago
pharmaphorum

Alkermes closing in on Biogen with MS rival

Alkermesaims towin aslice of the multiple sclerosis market with adrug to rival Biogen's big-selling Tecfidera, butless likely to produce unpleasant gastrointestinal side effects. The phenomenon nicknamed Tecfidera tummy is a major problem for ...
 pharmaphorum2 months ago
WKRB News

Nordea Investment Management AB Buys 17,156 Shares of Biogen Inc. (BIIB)

Nordea Investment Management AB increased its position in Biogen Inc. (NASDAQ:BIIB) by 4.4% during the third quarter, Holdings Channel reports. The institutional investor owned 410,214 shares of the biotechnology company's stock after buying an ...
 WKRB News1 hour ago 710,569 Shares in Biogen Inc. (BIIB) Acquired by The Manufacturers Life Insurance Company  WKRB News1 hour ago Jacobs Levy Equity Management Inc. Increases Position in Biogen Inc. (BIIB)  SleekMoney23 hours ago Greatmark Investment Partners Inc. Purchases 15 Shares of Biogen Inc. (BIIB)  SleekMoney1 day ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less